Menu
  • Join
  • Login
  • Contact
 

Search abstracts


DOSE ADJUSTMENT OF VANCOMYCIN USING CYSTATIN C IN SEPSIS WITH BACTERIAL MENINGITIS: A CASE REPORT

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: CHUMA, Masayuki (Tokushima University Hospital, Clinical Trial Center for Developmental Therapeutics, Japan)
  • Co-author(s): Masayuki Chuma: Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima , Japan
    Masateru Kondo: Department of Pharmacy, Tokushima University Hospital, Tokushima , Japan
    Yoshito Zamami: Department of Pharmacy, Tokushima University Hospital, Tokushima , Japan;Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima , Japan
    Kenshi Takechi: Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima , Japan
    Mitsuhiro Goda: Department of Pharmacy, Tokushima University Hospital, Tokushima , Japan
    Naoto Okada: Department of Pharmacy, Tokushima University Hospital, Tokushima , Japan
    Akitomo Shibata: Department of Pharmacy, Saiseikai Kumamoto Hospital, Kumamoto, Japan
    Mizuho Asada: Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan
    Jun Oto: Department of Emergency and Critical Care Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima , Japan
    Hiroaki Yanagawa: Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima , Japan
    Keisuke Ishizawa: Department of Pharmacy, Tokushima University Hospital, Tokushima , Japan;Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima , Japan
  • Abstract:

    Background

    Vancomycin (VCM) dosing needs to adjust accurately according to therapeutic drug monitoring (TDM) in bacterial meningitis. In determining VCM dosage, renal function is the most important factor. It is necessary to establish VCM dosing regimen that utilize novel marker of renal function because creatinine clearance (CrCl) may not be..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses